NYSE · Pharmaceutical Preparations
AbbVie Inc.ABBV
AbbVie Inc. (ABBV) is listed on NYSE; the SEC classifies it under "Pharmaceutical Preparations". For fiscal 2025 (ended Dec 31, 2025) it reported revenue of $61.16B, up 8.6% from fiscal 2024. Net income was $4.23B, a net margin of 6.9%. At fiscal year end it had total assets of $133.96B and stockholders' equity of -$3.27B (-2.4% of assets).
Company profile
- Ticker
- ABBV
- Exchange
- NYSE
- Industry (SIC)
- Pharmaceutical PreparationsSIC 2834
- Fiscal year end
- December 31
- Headquarters
- North Chicago, IL
- Incorporated in
- DE
- SEC filer category
- Large accelerated filer
- SEC CIK
- 1551152
Key financials (annual, 10-K)
| Key financials (annual, 10-K) | FY2025ended Dec 31, 2025 | FY2024ended Dec 31, 2024 | FY2023ended Dec 31, 2023 | FY2022ended Dec 31, 2022 | FY2021ended Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.2B |
| Revenue growth (YoY) | +8.57% | +3.71% | -6.44% | +3.30% | — |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| Net income growth (YoY) | -1.22% | -12.03% | -58.91% | +2.55% | — |
| Net margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% |
| Diluted EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B |
| Total liabilities | — | — | — | — | — |
| Stockholders' equity | -$3.27B | $3.33B | $10.36B | $17.25B | $15.41B |
| Equity ratio (equity / assets) | -2.4% | 2.5% | 7.7% | 12.4% | 10.5% |
| Cash and cash equivalents | $5.23B | $5.52B | $12.81B | $9.2B | $9.75B |
| Shares outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
Values as reported in each fiscal year's Form 10-K (XBRL data on SEC EDGAR); growth and ratios are computed from those values. Revenue is the total revenue figure the company tagged (omitted when the only figure tagged is evidently partial, e.g. below net income); growth is only shown between consecutive ~12-month fiscal years reported with the same revenue measure. Per-share figures and share counts are as reported and not adjusted for later stock splits. — = not reported.
Recent SEC filings
All filings on SEC EDGAR- 10-QQuarterly reportPeriod: Sep 30, 2026Filed: Nov 3, 2026
- 8-KCurrent reportPeriod: Oct 28, 2026Filed: Nov 2, 2026
- 8-KCurrent reportFiled: Oct 30, 2026
- 8-KCurrent reportPeriod: Oct 14, 2026Filed: Oct 15, 2026
- 8-KCurrent reportFiled: Oct 5, 2026
- 8-KCurrent reportFiled: Sep 3, 2026
- 8-KCurrent reportFiled: Aug 18, 2026
- 8-KCurrent reportPeriod: Aug 4, 2026Filed: Aug 5, 2026
- 10-QQuarterly reportPeriod: Jun 30, 2026Filed: Aug 3, 2026
- 8-KCurrent reportFiled: Jul 31, 2026
Frequently asked questions
What does AbbVie Inc. do?
The SEC classifies AbbVie Inc. under Standard Industrial Classification (SIC) code 2834, "Pharmaceutical Preparations". It is headquartered in North Chicago, IL. It is incorporated in DE. In fiscal 2025 it reported revenue of $61.16B and net income of $4.23B in its annual 10-K report.
What was AbbVie Inc.'s revenue in 2025?
AbbVie Inc. reported revenue of $61.16B for fiscal 2025, which ended Dec 31, 2025, up 8.6% from $56.33B in fiscal 2024, according to its annual 10-K report filed with the SEC on Feb 20, 2026.
What was AbbVie Inc.'s net income in 2025?
AbbVie Inc. reported net income of $4.23B for fiscal 2025, a net margin of 6.9% of revenue.
Where is AbbVie Inc. listed?
According to the SEC, AbbVie Inc.'s ticker ABBV is listed on NYSE.
When does AbbVie Inc.'s fiscal year end?
According to the SEC, AbbVie Inc.'s fiscal year ends on December 31; its latest reported fiscal year (2025) ended Dec 31, 2025.
Companies in the same industry
All US stocksSource: SEC EDGAR · Last updated:
Ver en españolNot investment advice: This page shows financial data that companies reported to the US Securities and Exchange Commission, for information only. It is not investment advice or a recommendation to buy or sell any security, and it shows no stock prices. Data may be incomplete, restated or out of date — check the original filings on SEC EDGAR before making decisions.